vp laboratory lecithin (paziņots 2013.) kapsula
ražots vācijā pēc vp laboratory ltd. pasūtījuma - kapsula
vp laboratory omega 3-6-9 (paziņots 2013.) kapsula
vp laboratory ltd. - kapsula
vp laboratory fish oil (paziņots 2013.) kapsula
vp laboratory ltd. - kapsula
vp laboratory glucosamine & chondroitin (paziņots 2012.) tablete
vp laboratory ltd. - tablete
vp laboratory coq10 (paziņots 2012.) kapsula
vp laboratory ltd. - kapsula
goldman laboratories vitamin d complex liposomal encapsulation (2020.) kapsula
goldman laboratories ltd - kapsula
goldman laboratories glutathione liposomal encapsulation (2020.) kapsula
goldman laboratories ltd - kapsula
goldman laboratories vitamin c liposomal encapsulation (2020.) kapsula
goldman laboratories ltd - kapsula
goldman laboratories liposomal vitamin c (2020.) kapsula
goldman laboratories ltd - kapsula
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - cūkas - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.